Jane Street’s Context Therapeutics CNTX Stock Holding History

Jane Street’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.14M	Buy	+436,931	New	+$1.02M	﹤0.01%	6220
2025 Q1	–	Sell	-27,395	Closed	-$28.8K	–	9561
2024 Q4	$28.8K	Buy	+27,395	New	+$47.4K	﹤0.01%	9087
2023 Q1	–	Sell	-19,827	Closed	-$12.9K	–	9134
2022 Q4	$12.9K	Sell	19,827 -52,233	-72%	-$56.3K	﹤0.01%	8704
2022 Q3	$80K	Buy	+72,060	New	+$130K	﹤0.01%	8751

Other funds holding CNTX

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Jane Street's CNTX Position: Q1 2026 in Review

Jane Street opened a new position in Context Therapeutics (CNTX) in Q1 2026: 436,931 shares worth $1.14M. The stake represents ﹤0.01% of the portfolio and ranks #6220 among its holdings. This is a return to the name: Jane Street previously reported a position in CNTX as recently as Q4 2024.

Jane Street first reported a position in CNTX in Q3 2022 and has held it in 4 quarters since. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

Jane Street held 436,931 shares of Context Therapeutics worth $1.14M as of Q1 2026.
Context Therapeutics was a new Jane Street position in Q1 2026.
Context Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #6220 holding.
Jane Street first reported a position in Context Therapeutics in Q3 2022 and has held it in 4 quarters since.
59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.